Publicaciones en colaboración con investigadoras/es de University of Auckland (50)

2024

  1. 2023 EULAR recommendations on imaging in diagnosis and management of crystal-induced arthropathies in clinical practice

    Annals of the Rheumatic Diseases

2023

  1. Genetic architecture of the inflammatory bowel diseases across East Asian and European ancestries

    Nature Genetics, Vol. 55, Núm. 5, pp. 796-806

  2. Outcome reporting in randomized trials in gout: A systematic scoping review from the OMERACT gout working group assessing the uptake of the core outcome set

    Seminars in Arthritis and Rheumatism, Vol. 60

  3. The 2023 ACR/EULAR Classification Criteria for Calcium Pyrophosphate Deposition Disease

    Arthritis and Rheumatology, Vol. 75, Núm. 10, pp. 1703-1713

  4. The 2023 ACR/EULAR classification criteria for calcium pyrophosphate deposition disease

    Annals of the Rheumatic Diseases, Vol. 82, Núm. 10, pp. 1248-1257

2022

  1. Identifying Potential Classification Criteria for Calcium Pyrophosphate Deposition Disease: Item Generation and Item Reduction

    Arthritis Care and Research, Vol. 74, Núm. 10, pp. 1649-1658

2021

  1. Correction to: Trans-ancestral dissection of urate- and gout-associated major loci SLC2A9 and ABCG2 reveals primate-specific regulatory effects (Journal of Human Genetics, (2021), 66, 2, (161-169), 10.1038/s10038-020-0821-z)

    Journal of Human Genetics

  2. Flare rate thresholds for patient assessment of disease activity states in Gout

    Journal of Rheumatology, Vol. 48, Núm. 2, pp. 293-298

  3. Trans-ancestral dissection of urate- and gout-associated major loci SLC2A9 and ABCG2 reveals primate-specific regulatory effects

    Journal of Human Genetics, Vol. 66, Núm. 2, pp. 161-169

  4. Which factors predict discordance between a patient and physician on a gout flare?

    Rheumatology (United Kingdom), Vol. 60, Núm. 2, pp. 773-779

2020

  1. Systematic genetic analysis of early-onset gout: ABCG2 is the only associated locus

    Rheumatology (United Kingdom), Vol. 59, Núm. 9, pp. 2544-2549

2019

  1. Combination urate-lowering therapy in the treatment of gout: What is the evidence?

    Seminars in Arthritis and Rheumatism, Vol. 48, Núm. 4, pp. 658-668

  2. Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study

    Arthritis Research and Therapy, Vol. 21, Núm. 1

  3. Gout

    Nature Reviews Disease Primers, Vol. 5, Núm. 1

  4. Gout

    Rheumatic Disease Clinics of North America, Vol. 45, Núm. 4, pp. 583-591

  5. Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout

    Annals of the Rheumatic Diseases, Vol. 78, Núm. 11, pp. 1592-1600

  6. Gout, Hyperuricemia, and Crystal-Associated Disease Network Consensus Statement Regarding Labels and Definitions for Disease Elements in Gout

    Arthritis Care and Research, Vol. 71, Núm. 3, pp. 427-434

2018

  1. Brief Report: Validation of a Definition of Flare in Patients With Established Gout

    Arthritis and Rheumatology, Vol. 70, Núm. 3, pp. 462-467

2017

  1. Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: An international case-cohort study

    European Respiratory Journal, Vol. 50, Núm. 2

  2. Global, regional, and national age-sex specifc mortality for 264 causes of death, 1980-2016: A systematic analysis for the Global Burden of Disease Study 2016

    The Lancet, Vol. 390, Núm. 10100, pp. 1151-1210